Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from OKYO Pharma Limited Sponsored ADR ( (OKYO) ) is now available.
On October 16, 2025, OKYO Pharma Limited announced that Panetta Partners Limited, in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 210,000 of the company’s ordinary shares on NASDAQ, increasing his total holding to 10,382,677 shares. This acquisition underscores confidence in the company’s strategic direction and its ongoing development of urcosimod, which has shown promising results in Phase 2 trials for treating neuropathic corneal pain and dry eye disease.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.
OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and dry eye disease. The company is working on urcosimod, a lipid-conjugated chemerin peptide agonist, designed to treat these ocular conditions. OKYO’s ordinary shares are listed on the NASDAQ Capital Market.
Average Trading Volume: 137,775
Technical Sentiment Signal: Buy
Current Market Cap: $77.85M
See more data about OKYO stock on TipRanks’ Stock Analysis page.